Advertisement
BCRX or CYCC or GNFT
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BCRX’s FA Score shows that 0 FA rating(s) are green whileCYCC’s FA Score has 0 green FA rating(s), and GNFT’s FA Score reflects 1 green FA rating(s).
- BCRX’s FA Score: 0 green, 5 red.
- CYCC’s FA Score: 0 green, 5 red.
- GNFT’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BCRX’s TA Score shows that 3 TA indicator(s) are bullish while CYCC’s TA Score has 3 bullish TA indicator(s), and GNFT’s TA Score reflects 2 bullish TA indicator(s).
- BCRX’s TA Score: 3 bullish, 4 bearish.
- CYCC’s TA Score: 3 bullish, 6 bearish.
- GNFT’s TA Score: 2 bullish, 5 bearish.
Price Growth
BCRX (@Biotechnology) experienced а -7.02% price change this week, while CYCC (@Biotechnology) price change was -39.40% , and GNFT (@Biotechnology) price fluctuated -4.55% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +0.14%. For the same industry, the average monthly price growth was +15.55%, and the average quarterly price growth was +36.18%.
Reported Earning Dates
BCRX is expected to report earnings on Oct 29, 2025.
CYCC is expected to report earnings on May 14, 2025.
GNFT is expected to report earnings on Nov 20, 2025.
Industries' Descriptions
@Biotechnology (+0.14% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| BCRX | CYCC | GNFT | |
| Capitalization | 1.67B | 15.4M | 199M |
| EBITDA | 47.6M | -12.68M | N/A |
| Gain YTD | 5.718 | -89.229 | 2.288 |
| P/E Ratio | N/A | 0.23 | 110.84 |
| Revenue | 503M | 14K | N/A |
| Total Cash | 295M | 93K | N/A |
| Total Debt | 795M | 9K | N/A |
BCRX | CYCC | GNFT | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 54 | 98 | 64 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 35 Fair valued | 77 Overvalued | 83 Overvalued | |
PROFIT vs RISK RATING 1..100 | 84 | 100 | 100 | |
SMR RATING 1..100 | 100 | 100 | 96 | |
PRICE GROWTH RATING 1..100 | 61 | 40 | 57 | |
P/E GROWTH RATING 1..100 | 100 | 98 | 2 | |
SEASONALITY SCORE 1..100 | n/a | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BCRX's Valuation (35) in the Biotechnology industry is somewhat better than the same rating for CYCC (77) and is somewhat better than the same rating for GNFT (83). This means that BCRX's stock grew somewhat faster than CYCC’s and somewhat faster than GNFT’s over the last 12 months.
BCRX's Profit vs Risk Rating (84) in the Biotechnology industry is in the same range as CYCC (100) and is in the same range as GNFT (100). This means that BCRX's stock grew similarly to CYCC’s and similarly to GNFT’s over the last 12 months.
GNFT's SMR Rating (96) in the Biotechnology industry is in the same range as BCRX (100) and is in the same range as CYCC (100). This means that GNFT's stock grew similarly to BCRX’s and similarly to CYCC’s over the last 12 months.
CYCC's Price Growth Rating (40) in the Biotechnology industry is in the same range as GNFT (57) and is in the same range as BCRX (61). This means that CYCC's stock grew similarly to GNFT’s and similarly to BCRX’s over the last 12 months.
GNFT's P/E Growth Rating (2) in the Biotechnology industry is significantly better than the same rating for CYCC (98) and is significantly better than the same rating for BCRX (100). This means that GNFT's stock grew significantly faster than CYCC’s and significantly faster than BCRX’s over the last 12 months.
| BCRX | CYCC | GNFT | |
|---|---|---|---|
| RSI ODDS (%) | 2 days ago 87% | 2 days ago 90% | N/A |
| Stochastic ODDS (%) | N/A | 2 days ago 87% | 2 days ago 90% |
| Momentum ODDS (%) | N/A | 2 days ago 90% | 2 days ago 79% |
| MACD ODDS (%) | 2 days ago 81% | N/A | 2 days ago 80% |
| TrendWeek ODDS (%) | 2 days ago 80% | 2 days ago 90% | 2 days ago 85% |
| TrendMonth ODDS (%) | 2 days ago 82% | 2 days ago 80% | 2 days ago 74% |
| Advances ODDS (%) | 25 days ago 79% | 10 days ago 82% | N/A |
| Declines ODDS (%) | 2 days ago 80% | 2 days ago 90% | 2 days ago 86% |
| BollingerBands ODDS (%) | 2 days ago 81% | 2 days ago 90% | 2 days ago 90% |
| Aroon ODDS (%) | 2 days ago 84% | 2 days ago 90% | 2 days ago 84% |
Advertisement
GNFT and
Correlation & Price change
A.I.dvisor tells us that GNFT and CVALF have been poorly correlated (+25% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that GNFT and CVALF's prices will move in lockstep.
| Ticker / NAME | Correlation To GNFT | 1D Price Change % | ||
|---|---|---|---|---|
| GNFT | 100% | -3.43% | ||
| CVALF - GNFT | 25% Poorly correlated | -1.96% | ||
| ORMP - GNFT | 25% Poorly correlated | -1.40% | ||
| GLTO - GNFT | 25% Poorly correlated | -2.58% | ||
| CAPR - GNFT | 24% Poorly correlated | -3.42% | ||
| FENC - GNFT | 24% Poorly correlated | -4.16% | ||
More | ||||